World's Best Scientists 2026 revealed!
Award Badge
Medicine
Ireland
2023

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 144 1447 1337 844 768 1101 76008

Francis J. Giles publications per year

The chart shows the history of publications by Francis J. Giles between 1990 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Francis J. Giles published across 37 years, from 1990 to 2026, averaging 35.4 papers a year. Output peaked at 151 publications in 2006. 16 of the 1,309 publications appeared in the last two years.

No. of publications
50 100 150
Bar chart. Horizontal axis: year, 1990 to 2026. Vertical axis: number of publications, 0 to 151. Peak 151 publications in 2006. 1990: 3 publications 1991: 7 publications 1992: 2 publications 1993: 0 publications 1994: 1 publication 1995: 3 publications 1996: 5 publications 1997: 3 publications 1998: 6 publications 1999: 18 publications 2000: 16 publications 2001: 30 publications 2002: 39 publications 2003: 81 publications 2004: 101 publications 2005: 78 publications 2006: 151 publications 2007: 91 publications 2008: 54 publications 2009: 53 publications 2010: 35 publications 2011: 29 publications 2012: 25 publications 2013: 21 publications 2014: 18 publications 2015: 32 publications 2016: 35 publications 2017: 76 publications 2018: 21 publications 2019: 38 publications 2020: 15 publications 2021: 11 publications 2022: 10 publications 2023: 123 publications 2024: 62 publications 2025: 14 publications 2026: 2 publications
1990 2026

1,309 publications in total across all disciplines

View publications per year as a table
Francis J. Giles: publications per year, 1990 to 2026
Year Publications
1990 3
1991 7
1992 2
1993 0
1994 1
1995 3
1996 5
1997 3
1998 6
1999 18
2000 16
2001 30
2002 39
2003 81
2004 101
2005 78
2006 151
2007 91
2008 54
2009 53
2010 35
2011 29
2012 25
2013 21
2014 18
2015 32
2016 35
2017 76
2018 21
2019 38
2020 15
2021 11
2022 10
2023 123
2024 62
2025 14
2026 2
Total 1,309
Download as CSV

Francis J. Giles publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Francis J. Giles sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 1,101–1,120 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 1,101 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54 1,101
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Francis J. Giles D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Francis J. Giles sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 144–145 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 144 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109 144
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2023 - Research.com Medicine in Ireland Leader Award
  • 2022 - Research.com Medicine in Ireland Leader Award

Overview

Francis J. Giles is affiliated with Northwestern University in the United States. Their research spans multiple areas primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. The scientist's work has a strong focus on molecular biology, oncology, hematology, genetics, and pathology and forensic medicine.

The scientist has contributed extensively to topics such as Wnt/β-catenin signaling in development and cancer, cancer-related gene regulation, protein degradation and inhibitors, chronic lymphocytic leukemia research, chronic myeloid leukemia treatments, cancer immunotherapy and biomarkers, and ubiquitin and proteasome pathways.

Frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Molecular Cancer Therapeutics
  • Leukemia

Notable recent papers authored or coauthored by Francis J. Giles include:

  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors (2020), Clinical Cancer Research
  • A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma (2021), Science Translational Medicine
  • Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer (2020), Nature Communications
  • Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734 (2020), Molecular Cancer Therapeutics
  • Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial (2021), Journal of Hematology & Oncology

Frequent coauthors collaborating with Francis J. Giles include Benedito A. Carneiro, Ludimila Cavalcante, Howard Safran, Steven Powell, and Andrew P. Mazar.

Best Publications

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

    Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

    Jennifer S. Carew;Steffan T. Nawrocki;Charissa N. Kahue;Hui Zhang

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • Wnt/beta-catenin pathway: modulating anticancer immune response.

    Sachin Gopalkrishna Pai;Sachin Gopalkrishna Pai;Benedito A. Carneiro;Jose Mauricio Mota;Ricardo Costa

  • Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

    Jennifer S. Carew;Francis J. Giles;Steffan T. Nawrocki

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

    Alvaro Aguayo;Elihu Estey;Elihu Estey;Hagop M Kantarjian;Hagop M Kantarjian;Taghi Mansouri;Taghi Mansouri

  • Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop M. Kantarjian;Jorge Cortes;Miloslav Beran

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Susan O'Brien
Susan O'Brien University of California, Irvine
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Deborah A. Thomas
Deborah A. Thomas The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Maher Albitar
Maher Albitar Genomic Testing Cooperative

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the field of medicine in the USA doesn't always mean traditional medical school. There are a variety of online programs that open doors to fulfilling careers in healthcare, offering greater flexibility and affordability.

Many students start their healthcare journey by taking billing and coding classes online. These courses offer a fast track into the administrative side of healthcare, with strong job growth and the option to work remotely.

For those interested in patient care, enrolling in an online nursing school can lead to an in-demand nursing career while offering substantial schedule flexibility for busy adults. If you wish to pursue advanced practice, there are also many cheapest nurse practitioner programs available online. These programs prepare graduates for expanded clinical roles in a variety of healthcare settings.

For nursing professionals seeking leadership or research roles, online PhD programs in nursing allow students to earn the highest credential in nursing from home. Each of these options offers pathways to rewarding careers and can be a stepping stone to further studies in medicine or healthcare.

Best Scientists Citing Francis J. Giles

Trending Scientists

Recently Published Articles